Novartis’s Cosentyx® (secukinumab) Approved by Scottish Medicines Consortium (SMC) for Treatment of Active Moderate to Severe Hidradenitis Suppurativa (HS)

On 12 February 2024, SMC published that it has approved Novartis’s Cosentyx® (secukinumab) for treatment of active moderate to severe HS, also known as acne inversa, in those adults who have previously had an inadequate response or lost response to conventional systemic adalimumab HS therapy.  

This comes months after Novartis announced, on 31 October 2023, that the FDA approved Cosentyx® (secukinumab) to treat moderate to severe HS in adults.